Rabbit antithymocyte globulin (rATG) is approved for the treatment of acute rejection
following kidney transplantation and is routinely administered as a series of 5-7 consecutive
daily doses via central intravenous catheter.Single large-doses of rATG have been shown to
have equivalent safety and efficacy profile compared to the standard daily protocol when used
as an induction agent but there are no reported experiences of its use for rejection
treatment. Plan to study a single-dose rATG infusion compared to standard rATG administration
including correlation to length of hospital stay and hospital costs.
Phase:
Phase 4
Details
Lead Sponsor:
The Methodist Hospital Research Institute The Methodist Hospital System